Prospect Venture Partners is a venture capital and private equity firm investing in biomedical technology companies that is headquartered in Palo Alto, California and was founded in 1997 by Alex Barkas.
According to the firms website (as of November 2019) they have raised over $1 billion in capital, led more than 50 funding rounds, and invest in seed and growth stage companies. Notable investments made by Prospect Venture Partners include: Amicus Therapeutics, Amira Pharmaceuticals, Cabochon, Complete Genomics, Gloucester Pharmaceuticals, Healtheon, Infinity Pharmaceuticals, Idun Pharmaceuticals, Intuitive Surgical, Kythera Biopharmaceuticals, SentreHeart, Rinat Neuroscience, Tinea Pharmaceuticals, Trubion, Visiogen, and Vitae Pharmaceuticals,
On July 30, 2001 Prospect Venture Partners announced raising $500 million for their third venture capital fund. The fund will be used to invest in early-stage biotechnology, biopharmaceutical, and medical devices companies. Prospect Venture Partners will use the fund to make investments in approximately 30 companies ranging in size from $10 to $15 million.